{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:58:56Z","timestamp":1781632736685,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nutr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver disease related to alcohol consumption and non-alcoholic fatty liver disease (NAFLD) are among the leading causes of liver fibrosis. Curcumin, due to its anti-fibrotic and anti-inflammatory effects, has been proposed as a potential therapeutic agent. However, its clinical application is limited by poor stability, solubility, and bioavailability. Nanocurcumin, a nano-formulated version of curcumin, overcomes these limitations. This study aims to evaluate the efficacy of Nanocurcumin supplementation in improving fibrosis, steatosis, inflammation, and metabolic status in patients with liver fibrosis of NAFLD origin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This double-blind, randomized, placebo-controlled trial is being conducted at the Gastroenterology Clinic of Shariati Hospital (Tehran, Iran). Fifty patients aged 30 to 70 years are enrolled and randomly assigned to the intervention or placebo group using a block balanced randomization method. The intervention group receives one capsule of Nanocurcumin (40\u00a0mg, twice daily), while the placebo group receives an identical placebo capsule. The primary outcomes include liver fibrosis and steatosis, assessed via FibroScan at baseline and at the end of the study. Secondary outcomes include changes in inflammatory markers, metabolic parameters, liver function tests, anthropometric measures, and blood pressure over the 16-week intervention period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial is currently ongoing. Recruitment is expected to be completed by the end of 2024, and the trial is anticipated to be fully completed by mid-2025. If Nanocurcumin supplementation demonstrates positive efficacy, it may serve as a potential therapeutic approach for patients with liver fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Iranian Registry of Clinical Trials IRCT20210427051098N2 (Available from: https:\/\/irct.behdasht.gov.ir).<\/jats:p>\n                    <jats:p>Date and version identifier: April 20, 2023; approved version by the IRCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40795-026-01252-0","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:54:21Z","timestamp":1770029661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of the nano curcumin supplementation on fibrosis, steatosis, inflammatory and metabolic status of liver fibrosis patients with non-alcoholic fatty liver origin: a study protocol for a double-blind randomized controlled trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Hadis","family":"Gerami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mozaffari-Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asieh","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ali","family":"Sohrabpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Pejman Hashemi","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Jambarsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-7340","authenticated-orcid":false,"given":"Sayyed Saeid","family":"Khayyatzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"11","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCRESAHA.121.319059","volume":"128","author":"Z Chen","year":"2021","unstructured":"Chen Z, Liu J, Zhou F, Li H, Zhang X-J, She Z-G, et al. Nonalcoholic fatty liver disease: an emerging driver of cardiac arrhythmia. Circul Res. 2021;128(11):1747\u201365.","journal-title":"Circul Res"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00592-019-01374-x","volume":"56","author":"A Mansour","year":"2019","unstructured":"Mansour A, Mohajeri-Tehrani MR, Samadi M, Gerami H, Qorbani M, Bellissimo N, et al. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol. 2019;56:1199\u2013207.","journal-title":"Acta Diabetol"},{"issue":"23","key":"1252_CR3","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.3748\/wjg.v20.i23.7260","volume":"20","author":"G\u00d6 Elpek","year":"2014","unstructured":"Elpek G\u00d6. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World J Gastroenterology: WJG. 2014;20(23):7260.","journal-title":"World J Gastroenterology: WJG"},{"key":"1252_CR4","doi-asserted-by":"crossref","unstructured":"Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Annals Translational Med. 2021;9(8):729.","DOI":"10.21037\/atm-20-4354"},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40139-013-0019-6","volume":"1","author":"JX Jiang","year":"2013","unstructured":"Jiang JX, T\u00f6r\u00f6k NJ. Liver injury and the activation of the hepatic myofibroblasts. Curr Pathobiology Rep. 2013;1:215\u201323.","journal-title":"Curr Pathobiology Rep"},{"issue":"11","key":"1252_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells8111419","volume":"8","author":"B Dewidar","year":"2019","unstructured":"Dewidar B, Meyer C, Dooley S, Meindl-Beinker N. TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis\u2014updated 2019. Cells. 2019;8(11):1419.","journal-title":"Cells"},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"615978","DOI":"10.3389\/fmed.2021.615978","volume":"8","author":"LJ Heyens","year":"2021","unstructured":"Heyens LJ, Busschots D, Koek GH, Robaeys G, Francque S. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med. 2021;8:615978.","journal-title":"Front Med"},{"issue":"1","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/hep.29721","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349\u201360.","journal-title":"Hepatology"},{"issue":"4","key":"1252_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.gastre.2019.11.006","volume":"43","author":"L Wu","year":"2020","unstructured":"Wu L, Shen Y, Li F. Non-invasive diagnosis of liver fibrosis: A review of current imaging modalities. Gastroenterolog\u00eda Y Hepatolog\u00eda (English Edition). 2020;43(4):211\u201321.","journal-title":"Gastroenterolog\u00eda Y Hepatolog\u00eda (English Edition)"},{"issue":"6","key":"1252_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4254\/wjh.v15.i6.755","volume":"15","author":"C-Y Zhang","year":"2023","unstructured":"Zhang C-Y, Liu S, Yang M. Treatment of liver fibrosis: Past, current, and future. World J Hepatol. 2023;15(6):755.","journal-title":"World J Hepatol"},{"issue":"1","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/hep.29724","volume":"68","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68(1):361\u201371.","journal-title":"Hepatology"},{"key":"1252_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.matbio.2018.02.017","volume":"68","author":"M Allinovi","year":"2018","unstructured":"Allinovi M, De Chiara L, Angelotti ML, Becherucci F, Romagnani P. Anti-fibrotic treatments: a review of clinical evidence. Matrix Biol. 2018;68:333\u201354.","journal-title":"Matrix Biol"},{"key":"1252_CR13","doi-asserted-by":"publisher","first-page":"262882","DOI":"10.3389\/fphar.2017.00186","volume":"8","author":"L Fang","year":"2017","unstructured":"Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017;8:262882.","journal-title":"Front Pharmacol"},{"key":"1252_CR14","doi-asserted-by":"crossref","unstructured":"Yoon YJ, Friedman SL, Lee YA, editors. Antifibrotic therapies: where are we now? Seminars in liver disease. Thieme Medical; 2016.","DOI":"10.1055\/s-0036-1571295"},{"issue":"1","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/abr.abr_147_16","volume":"7","author":"AH Rahmani","year":"2018","unstructured":"Rahmani AH, Alsahli MA, Aly SM, Khan MA, Aldebasi YH. Role of Curcumin in disease prevention and treatment. Adv Biomedical Res. 2018;7(1):38.","journal-title":"Adv Biomedical Res"},{"key":"1252_CR16","doi-asserted-by":"crossref","unstructured":"Chen Y, Lu Y, Lee RJ, Xiang G. Nano encapsulated curcumin: and its potential for biomedical applications. Int J Nanomed. 2020:3099\u2013120.","DOI":"10.2147\/IJN.S210320"},{"issue":"2","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.biomaterials.2010.08.112","volume":"32","author":"W Wu","year":"2011","unstructured":"Wu W, Shen J, Banerjee P, Zhou S. Water-dispersible multifunctional hybrid nanogels for combined Curcumin and photothermal therapy. Biomaterials. 2011;32(2):598\u2013609.","journal-title":"Biomaterials"},{"issue":"1\u20132","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drudis.2011.09.009","volume":"17","author":"MM Yallapu","year":"2012","unstructured":"Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discovery Today. 2012;17(1\u20132):71\u201380.","journal-title":"Drug Discovery Today"},{"key":"1252_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fphar.2019.00152","volume":"10","author":"KE Wong","year":"2019","unstructured":"Wong KE, Ngai SC, Chan KG, Lee LH, Goh BH, Chuah LH. Curcumin nanoformulations for colorectal cancer: a review. Front Pharmacol. 2019;10:152. https:\/\/doi.org\/10.3389\/fphar.2019.00152.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1252_CR20","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1039\/c7fo01814b","volume":"9","author":"S Peng","year":"2018","unstructured":"Peng S, Li Z, Zou L, Liu W, Liu C, McClements DJ. Improving Curcumin solubility and bioavailability by encapsulation in saponin-coated Curcumin nanoparticles prepared using a simple pH-driven loading method. Food Funct. 2018;9(3):1829\u201339. https:\/\/doi.org\/10.1039\/c7fo01814b.","journal-title":"Food Funct"},{"issue":"7","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/metabo12070639","volume":"12","author":"BM Sivani","year":"2022","unstructured":"Sivani BM, Azzeh M, Patnaik R, Pantea Stoian A, Rizzo M, Banerjee Y. Reconnoitering the therapeutic role of Curcumin in disease prevention and treatment: lessons learnt and future directions. Metabolites. 2022;12(7):639.","journal-title":"Metabolites"},{"issue":"1","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/pharmaceutics15010229","volume":"15","author":"LF Laurindo","year":"2023","unstructured":"Laurindo LF, de Carvalho GM, de Oliveira Zanuso B, Figueira ME, Direito R, de Alvares Goulart R, et al. Curcumin-based nanomedicines in the treatment of inflammatory and Immunomodulated diseases: an evidence-based comprehensive review. Pharmaceutics. 2023;15(1):229.","journal-title":"Pharmaceutics"},{"key":"1252_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10741-019-09854-6","volume":"25","author":"AM Gorabi","year":"2020","unstructured":"Gorabi AM, Hajighasemi S, Kiaie N, Rosano GM, Sathyapalan T, Al-Rasadi K, et al. Anti-fibrotic effects of Curcumin and some of its analogues in the heart. Heart Fail Rev. 2020;25:731\u201343.","journal-title":"Heart Fail Rev"},{"key":"1252_CR24","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical Res ed). 2013;346:e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"2","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1148\/radiol.2020192437","volume":"296","author":"RG Barr","year":"2020","unstructured":"Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the society of radiologists in ultrasound liver elastography consensus statement. Radiology. 2020;296(2):263\u201374. https:\/\/doi.org\/10.1148\/radiol.2020192437.","journal-title":"Radiology"},{"issue":"10","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s00261-019-02183-0","volume":"44","author":"M Chung","year":"2019","unstructured":"Chung M, Baird GL, Weiss KE, Beland MD. 2D shear wave elastography: measurement acquisition and reliability criteria in noninvasive assessment of liver fibrosis. Abdom Radiol (New York). 2019;44(10):3285\u201394. https:\/\/doi.org\/10.1007\/s00261-019-02183-0.","journal-title":"Abdom Radiol (New York)"},{"issue":"3","key":"1252_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.path.2023.04.002","volume":"16","author":"K Matsukuma","year":"2023","unstructured":"Matsukuma K, Yeh MM. Practical Guide, Challenges, and pitfalls in liver fibrosis staging. Surg Pathol Clin. 2023;16(3):457\u201372. https:\/\/doi.org\/10.1016\/j.path.2023.04.002.","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"1252_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12876-022-02176-2","volume":"22","author":"S Ebrahimi-Mousavi","year":"2022","unstructured":"Ebrahimi-Mousavi S, Alavian SM, Sohrabpour AA, Dashti F, Djafarian K, Esmaillzadeh A. The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. BMC Gastroenterol. 2022;22(1):102. https:\/\/doi.org\/10.1186\/s12876-022-02176-2.","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.Mss.0000078924.61453.Fb","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sj\u00f6str\u00f6m M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381\u201395. https:\/\/doi.org\/10.1249\/01.Mss.0000078924.61453.Fb.","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3945\/ajcn.113.068890","volume":"99","author":"T Eslamparast","year":"2014","unstructured":"Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535\u201342. https:\/\/doi.org\/10.3945\/ajcn.113.068890.","journal-title":"Am J Clin Nutr"},{"key":"1252_CR31","doi-asserted-by":"publisher","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4). https:\/\/doi.org\/10.3390\/cells9040875","DOI":"10.3390\/cells9040875"},{"key":"1252_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","volume":"15","author":"SC Gupta","year":"2013","unstructured":"Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15:195\u2013218.","journal-title":"AAPS J"},{"issue":"11","key":"1252_CR33","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ptr.5174","volume":"28","author":"Y Panahi","year":"2014","unstructured":"Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: A randomized double-blind placebo\u2010controlled trial. Phytother Res. 2014;28(11):1625\u201331.","journal-title":"Phytother Res"},{"issue":"10","key":"1252_CR34","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1016\/j.biomaterials.2013.12.090","volume":"35","author":"O Naksuriya","year":"2014","unstructured":"Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365\u201383.","journal-title":"Biomaterials"}],"container-title":["BMC Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40795-026-01252-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40795-026-01252-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40795-026-01252-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:32:24Z","timestamp":1781631144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40795-026-01252-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1186\/s40795-026-01252-0","relation":{},"ISSN":["2055-0928"],"issn-type":[{"value":"2055-0928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study will conducted according to the principles of the declaration of Helsinki. The current clinical trial has been approved by the research ethics committee (REC) of Shahid Sadoughi University of Medical Sciences (Yazd, Iran) (REC approval ID: IR. SSU. SPH.REC. 1401. 157). All participants will provide informed written consent before enrolment in the study (Supplementary). The intervention will be designed not to interfere with the routine treatment of patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"After finishing the study, the results of the study will be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}